title: Vaccines for Nontypeable Haemophilus influenzae: the Future Is Now.
abstract: Infections due to nontypeable Haemophilus influenzae result in enormous global morbidity in two clinical settings: otitis media in children and respiratory tract infections in adults with chronic obstructive pulmonary disease (COPD). Recurrent otitis media affects up to 20% of children and results in hearing loss, delays in speech and language development and, in developing countries, chronic suppurative otitis media. Infections in people with COPD result in clinic and emergency room visits, hospital admissions, and respiratory failure. An effective vaccine would prevent morbidity, help control health care costs, and reduce antibiotic use, a major contributor to the global crisis in bacterial antibiotic resistance. The widespread use of the pneumococcal conjugate vaccines is causing a relative increase in H. influenzae otitis media. The partial protection against H. influenzae otitis media induced by the pneumococcal H. influenzae protein D conjugate vaccine represents a proof of principle of the feasibility of a vaccine for nontypeable H. influenzae. An ideal vaccine antigen should be conserved among strains, have abundant epitopes on the bacterial surface, be immunogenic, and induce protective immune responses. Several surface proteins of H. influenzae have been identified as potential vaccine candidates and are in various stages of development. With continued research, progress toward a broadly effective vaccine to prevent infections caused by nontypeable H. influenzae is expected over the next several years.
authors: Division of Infectious Diseases, Department of Medicine, Clinical and Translational Research Center, Department of Microbiology and Immunology, University at Buffalo, State University of New York, Buffalo, New York, USA murphyt@buffalo.edu.
authors: Timothy F
authors: TF
authors: Murphy
mesh_terms: D000328:Adult; D002648:Child; D006192:Haemophilus Infections / Q000276:immunology / Q000517:prevention & control*; D018073:Haemophilus Vaccines / Q000276:immunology; D006193:Haemophilus influenzae / Q000276:immunology*; D006801:Humans; D010033:Otitis Media / Q000276:immunology / Q000517:prevention & control*; D022242:Pneumococcal Vaccines / Q000276:immunology; D029424:Pulmonary Disease, Chronic Obstructive / Q000150:complications; D012141:Respiratory Tract Infections / Q000150:complications / Q000276:immunology / Q000517:prevention & control*; D018074:Vaccines, Conjugate / Q000276:immunology
chemical_list: D018073:Haemophilus Vaccines; D022242:Pneumococcal Vaccines; D018074:Vaccines, Conjugate